The 2017 APSARD Annual Meeting was held from January 13-15, 2017 at the Mayflower Hotel in Washington D.C. with approximately 350 researchers and clinicians in attendance.
Ongoing clinical and scientific advances have transformed the field of ADHD. Substantial knowledge has been gained on the neurobiology, heritability, environmental, persistence, comorbidity, psychotherapeutic and pharmacological treatment of ADHD in children, adolescents and adults. This CME-accredited course will feature nationally and internationally renowned ADHD faculty who will educate participants on recent research findings relevant to clinical practice with a focus on improving the quality of care for all patients with ADHD & related disorders.
Needs Assessment: ADHD is a common disorder of childhood that is typically characterized by symptoms of inattentiveness, impulsivity and hyperactivity, as well as other psychological, social, and emotional difficulties. ADHD is associated with substantial functional and quality of life impairments. This includes impaired academic, social and work performance, as well as emotional distress for family members and caregivers.
Program Description: This two-day activity will provide a comprehensive summary of the most recent data in ADHD. The education will be designed such that faculty experts will present data pertaining to guidelines, treatment of ADHD in diverse patient populations.
The learning objectives for the 2017 APSARD Annual Meeting are identified as:
1. Appreciate advances in the neurobiological mechanisms underlying ADHD and understand how these may be modified by treatment.
2. Understand new findings regarding the longitudinal course of ADHD and the possible ramifications of studies suggesting onset in late adolescence or adulthood.
3. Understand issues regarding diagnosis and treatment of ADHD in preschool children, and new studies being developed to assess treatment response in this age group.
4. Recognize issues regarding the clinical presentation and management of ADHD in college students.
This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.
Continuing Education Credit Information:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and APSARD is accredited by the ACCME to provide continuing medical education for physicians.
Amedco designates this live activity for a maximum of 13 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This course is co-provided by Amedco and APSARD. Maximum of 13 contact hours.
This course is co-sponsored by Amedco and APSARD. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 13 hours.
Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 6/24/2016 to 6/24/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits.
Social workers participating in this course may receive up to 13 clinical continuing education clock hours.
Participants must complete an attendance/evaluation form in order to receive a certificate of completion/attendance. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.